For the quarter ending 2025-09-30, SPRO has $54,170K in assets. $27,676K in debts. $48,616K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 48,616 | 31,194 | ||
| Collaboration receivable, current - related party | 868 | 24,453 | ||
| Other receivables | 1,591 | 2,460 | ||
| Prepaid expenses and other current assets | 1,248 | 1,295 | ||
| Total current assets | 52,323 | 59,402 | ||
| Operating lease right of use assets | 1,694 | 2,564 | ||
| Other assets | 153 | 153 | ||
| Total assets | 54,170 | 62,119 | ||
| Accounts payable | 1,395 | 780 | ||
| Accrued expenses and other current liabilities | 7,809 | 6,727 | ||
| Operating lease liabilities | 1,899 | 1,844 | ||
| Income taxes payable | 163 | 163 | ||
| Deferred revenue, current | 0 | 0 | ||
| Deferred revenue, current - related party | 2,383 | 5,431 | ||
| Total current liabilities | 13,649 | 14,945 | ||
| Non-current operating lease liabilities | 1,452 | 1,771 | ||
| Deferred revenue, non-current | 12,575 | 12,575 | ||
| Deferred revenue, non-current - related party | 0 | 0 | ||
| Total liabilities | 27,676 | 29,291 | ||
| Common stock, 0.001 par value 120,000,000 shares authorized as of september 30, 2025 and december 31, 2024 56,311,795 shares issued and outstanding as of september 30, 2025 and 54,593,527 shares issued and outstanding as of december 31, 2024 | 56 | 56 | ||
| Additional paid-in capital | 509,024 | 507,976 | ||
| Accumulated deficit | -482,586 | -475,204 | ||
| Total stockholders' equity | 26,494 | 32,828 | ||
| Total liabilities and stockholders' equity | 54,170 | 62,119 | ||
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)